REV-ERB agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Master of Science, Master of Business Administration, Master of Health Administration, Doctor of medical laboratory science for specialization, education and management roles. Doctor of Philosophy for management and directorship roles in the clinical laboratory as well as for academic research and professorship. Doctors of Philosophy holding a degree in a biological science, and who are board certified by a CLIA-approved entity, are qualified as a medical laboratory director. Doctor of Medicine or Doctor of clinical laboratory Science - this is the position that qualifies an individual to oversee or direct almost all types of clinical laboratories. Under U.S. CLIA laws, a requirement of at least year of clinical laboratory experience (any MD) or pathology residency must be met. In the United Kingdom the Modernising Scientific Careers (MSC) programme sets out a training and career framework for the healthcare science workforce. One aspect of the framework was the formalisation of training to develop talented clinical scientists to undertake Higher Specialist Scientist Training (HSST) programmes to prepare them for roles as consultant clinical scientists. Training through the Higher Specialist Scientist Training pathway is discipline specific. For life science disciplines (immunology, microbiology, virology, haematology, biochemistry) the training curriculum and formal examinations are administered by the Royal College of Pathologists.
=== Cocaine dependence === In combination with samidorphan or naltrexone (μ-opioid receptor antagonists), buprenorphine is under investigation for the treatment of cocaine dependence, and recently demonstrated effectiveness for this indication in a large-scale (n = 302) clinical trial (at a high buprenorphine dose of 16 mg, but not a low dose of 4 mg).
Orthofluorofentanyl (o-fluorofentanyl, 2-fluorofentanyl) is an opioid analgesic that is an analog of fentanyl and has been sold online as a designer drug. While the structural isomer p-fluorofentanyl was one of the first illicit fentanyl analogues identified in 1981, Orthofluorofentanyl did not appear on the illicit market until August 2016.
Sources: en.wikipedia.org
For promotion from the Secondary level (Class IX-X) to the Senior Secondary level (Class XI-XII), a student must obtain, for all subjects (or best five if six subjects are taken), 33% overall, without any minimum theory mark requirement. Initially, the passing criteria were set such that a student had to get 33% in both the theory and practical components. However, an exemption was initially granted to students who wrote the exam in 2018, as they had gone through the old CCE system the previous year. However, CBSE later extended this relief for students writing the exam from 2019 and later as well. Students who do not manage to pass up to two subjects can write the compartment in those subjects in July. Those who fail a compartment or three or more subjects must retake all subjects taken the following year.
Furthermore, exceptionally in this group, reactivity with boron decreases down the group: lithium reacts completely at 700 °C, but sodium at 900 °C and potassium not until 1200 °C, and the reaction is instantaneous for lithium but takes hours for potassium. Rubidium and caesium borides have not even been characterised. Various phases are known, such as LiB10, NaB6, NaB15, and KB6. Under high pressure the boron–boron bonding in the lithium borides changes from following Wade's rules to forming Zintl anions like the rest of group 13.
Until 13 July 2013, the import and sale of absinthe technically required a special permit, since "oil of wormwood, being an essential oil obtained from plants of the genus Artemisia, and preparations containing oil of wormwood" were listed as item 12A, Schedule 8, Regulation 5H of the Customs (Prohibited Imports) Regulations 1956 (Cth). These controls have now been repealed, and permission is no longer required.
Sources: en.wikipedia.org
=== Legal issues === On April 14, 2013, Hart was charged on suspicion of drunk driving after his vehicle nearly collided with a tanker truck on a Southern California freeway. He failed a field sobriety test and was booked for misdemeanor driving under the influence. On August 5, he was sentenced to three years of probation after pleading no contest to one count of driving under the influence of alcohol.
At atmospheric levels of ambient CO2 the table indicates that the solution will be slightly alkaline with a maximum CaCO3 solubility of 47 mg/L. As ambient CO2 partial pressure is reduced below atmospheric levels, the solution becomes more and more alkaline. At extremely low PCO2, dissolved CO2, bicarbonate ion, and carbonate ion largely evaporate from the solution, leaving a highly alkaline solution of calcium hydroxide, which is more soluble than CaCO3. For PCO2 = 10−12 atm, the [Ca2+][OH−]2 product is still below the solubility product of Ca(OH)2 (8×10−6). For still lower CO2 pressure, Ca(OH)2 precipitation will occur before CaCO3 precipitation. As ambient CO2 partial pressure increases to levels above atmospheric, pH drops, and much of the carbonate ion is converted to bicarbonate ion, which results in higher solubility of Ca2+. The effect of the latter is especially evident in day-to-day life of people who have hard water. Water in aquifers underground can be exposed to levels of CO2 much higher than atmospheric. As such, water percolates through calcium carbonate rock, the CaCO3 dissolves according to one of the trends above. When that same water then emerges from the tap, in time, it comes into equilibrium with CO2 levels in the air by outgassing its excess CO2. The calcium carbonate becomes less soluble as a result, and the excess precipitates as lime scale. This same process is responsible for the formation of stalactites and stalagmites in limestone caves.
=== Generating diagnostic hypotheses === Determining which pieces of information are most important to the next phase of the diagnostic process is of vital importance. It is during this stage that clinical bias like anchoring or premature closure may be introduced. Once key findings are determined, they are compared to profiles of possible diseases. These profiles include findings that are typically associated with the disease and are based on the likelihood that someone with the disease has a particular symptom. A list of potential diagnoses is termed the "differential diagnosis" for the patient and is typically ordered from most likely to least likely, with special attention given to those conditions that have dire consequences for the patient if they were missed. Epidemiology and endemic conditions are also considered in creating and evaluating the list of diagnoses. The list is dynamic and changes as the doctor obtains additional information that makes a condition more ("rule-in") or less ("rule-out") likely based on the disease profile. The list is used to determine what information will be acquired next, including which diagnostic test or imaging modality to order. The selection of tests is also based on the doctor's knowledge of the specificity and sensitivity of a particular test. An important part of this process is knowledge of the various ways that a disease can present in a patient. This knowledge is gathered and shared to add to the database of disease profiles used by doctors. This is especially important in rare diseases.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.